Nuvation Bio Inc.
NUVBNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 | — | — | — |
| Operating income | −$213.1M | −$592.6M | −$99.8M | −$119.7M | −$93.3M | −$3.1M |
| Net income | −$204.6M | −$567.9M | −$75.8M | −$104.2M | −$86.8M | −$3.1M |
| Total assets | $594.8M | $540.6M | $621.5M | $672.1M | $776.2M | $145.0M |
| Total liabilities | $289.1M | $76.8M | $16.4M | $17.1M | $30.2M | $2.8M |
| Equity | $305.7M | $463.8M | $605.1M | $655.1M | $746.0M | $0 |
| EPS (diluted) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 | — |
| Shares out. | 337.8M | 337.8M | 219.0M | 218.6M | 217.9M | 149.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −338.7%
- Net margin
- −325.3%
- Return on equity
- −66.9%
- Return on assets
- −34.4%
- Return on capital (ROCE)
- −41.6%
- Liabilities / assets
- 48.6%
- Debt / equity
- 0.95×
- Book value / share
- $0.90
- Revenue growth (YoY)
- 699.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -2.01distress
- Accruals / assets
- −5.2%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2024-06-07A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
- Phase 2Active Not Recruitingreadout ~2025-06-11Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
- Phase 1/2Active Not Recruitingreadout ~2027-03Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
- Phase 3Recruitingreadout ~2028-12-01SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Phase 3Recruitingreadout ~2029-01A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase 3Recruitingreadout ~2030-08-30Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Fmr LlcPassive (13G)May 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 51.5M | 10.0 | +1.7% |
| Apr 30, 2026 | 50.6M | 13.0 | +0.7% |
| Apr 15, 2026 | 50.3M | 19.0 | +3.2% |
| Mar 31, 2026 | 48.7M | 13.4 | -1.4% |
| Mar 13, 2026 | 49.5M | 7.1 | +5.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 27, 2026
- Results of operationsMay 4, 2026
- Results of operationsMar 2, 2026
- Entered a material agreement · Results of operations · Regulation FD disclosureJan 12, 2026
- Regulation FD disclosure · Other material eventNov 26, 2025
- Regulation FD disclosure · Other material eventNov 17, 2025
- Results of operationsNov 3, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.